Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Remitogen and Rituxan assessed in combination in cancer patients

Oct. 31, 2001

Therion secures financing to advance lead cancer vaccine into phase III trials

Oct. 31, 2001

Biomira to commence interim analysis of Theratope vaccine in the third quarter of 2002

Oct. 25, 2001

Phase II trial initiated for BLP25 vaccine for prostate cancer

Oct. 25, 2001

AltaRex reviews novel technology and OvaRex data at Engineered Antibodies conference

Oct. 24, 2001

Cell Genesys commences phase II trial of GVAX vaccine for pancreatic cancer

Oct. 23, 2001

CPMP issues positive opinion regarding MabThera for treatment of aggressive NHL

Oct. 22, 2001

Phase II clinical trials commence with Transgene's immunotherapeutic for cervical cancer

Oct. 19, 2001

InterMune and Boehringer Ingelheim expand partnership to develop product for ovarian cancer

Oct. 18, 2001

Oncophage enters fast track development

Oct. 16, 2001

Popular Stories

Today's news in brief
BioWorld
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...